Randomized phase II study of nimotuzumab, an anti-EGFR antibody, plus irinotecan in patients with 5-fluorouracil-based regimen-refractory advanced or recurrent gastric cancer in Korea and Japan: Preliminary results

被引：8
|
作者：
Kim, Y. H.
Sasaki, Y.
Lee, K. H.
Rha, S. Y.
Park, S.
Boku, N.
Komatsu, Y.
Kim, T.
Kim, S.
Sakata, Y.
机构：
[1] Korea Univ, Coll Med, Seoul 136705, South Korea
[2] Saitama Med Univ, Int Med Ctr, Saitama, Japan
[3] Yeungnam Univ Hosp, Taegu, South Korea
[4] Yonsei Univ, Coll Med, Canc Metastasis Res Ctr, Yonsei Canc Ctr, Seoul, South Korea
[5] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea
[6] Shizuoka Canc Ctr, Shizuoka, Japan
[7] Hokkaido Univ Hosp, Dept Canc Ctr, Sapporo, Hokkaido, Japan
[8] Seoul Natl Univ Hosp, Dept Internal Med, Seoul 110744, South Korea
[9] Kyung Hee Univ Hosp, Seoul, South Korea
[10] Misawa Municipal Hosp, Misawa, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 04期
关键词：
D O I：
10.1200/jco.2011.29.4_suppl.87
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
87
引用
收藏
页数：1
相关论文
共 50 条
  • [31] A Phase II Study of Irinotecan, Continuous 5-Fluorouracil, and Leucovorin (FOLFIRI) Combination Chemotherapy for Patients With Recurrent or Metastatic Gastric Cancer Previously Treated With a Fluoropyrimidine-Based Regimen
    Kim, Seok Hyun
    Lee, Gyeong-Won
    Go, Se Il
    Cho, Su Hee
    Kim, Hyun Jin
    Kim, Hun Gu
    Kang, Jung Hun
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2010, 33 (06): : 572 - 576
  • [32] Docetaxel combined with irinotecan or 5-fluorouracil in patients with advanced oesophago-gastric cancer: a randomised phase II study
    Roy, A.
    Cunningham, D.
    Hawkins, R.
    Sorbye, H.
    Adenis, A.
    Barcelo, J-R
    Lopez-Vivanco, G.
    Adler, G.
    Canon, J-L
    Lofts, F.
    Castanon, C.
    Fonseca, E.
    Rixe, O.
    Aparicio, J.
    Cassinello, J.
    Nicolson, M.
    Mousseau, M.
    Schalhorn, A.
    D'Hondt, L.
    Kerger, J.
    Hossfeld, D. K.
    Giron, C. Garcia
    Rodriguez, R.
    Schoffski, P.
    Misset, J-L
    BRITISH JOURNAL OF CANCER, 2012, 107 (03) : 435 - 441
  • [33] Docetaxel combined with irinotecan or 5-fluorouracil in patients with advanced oesophago-gastric cancer: a randomised phase II study
    A Roy
    D Cunningham
    R Hawkins
    H Sörbye
    A Adenis
    J-R Barcelo
    G Lopez-Vivanco
    G Adler
    J-L Canon
    F Lofts
    C Castanon
    E Fonseca
    O Rixe
    J Aparicio
    J Cassinello
    M Nicolson
    M Mousseau
    A Schalhorn
    L D'Hondt
    J Kerger
    D K Hossfeld
    C Garcia Giron
    R Rodriguez
    P Schoffski
    J-L Misset
    British Journal of Cancer, 2012, 107 : 435 - 441
  • [34] Capecitabine in combination with oxaliplatin or with irinotecan in elderly patients with advanced colorectal cancer: Preliminary results of a randomized phase ii study
    Rosati, G.
    Cordio, S.
    Bordonaro, R.
    Gebbia, V.
    Borsellino, N.
    Giannitto, G.
    Rinaldi, A.
    Reggiardo, G.
    Manzione, L.
    ANNALS OF ONCOLOGY, 2007, 18 : 20 - 20
  • [35] Capecitabine in combination with oxaliplatin or with irinotecan in elderly patients with advanced colorectal cancer: Preliminary results of a randomized phase II study
    Rosati, G.
    Cordio, S.
    Bordonaro, R.
    Gebbia, V
    Rinaldi, A.
    Giannitto, G.
    Borsellino, N.
    Reggiardo, G.
    Manzione, L.
    ANNALS OF ONCOLOGY, 2007, 18 : 189 - 189
  • [36] Capecitabine in combination with oxaliplatin or with irinotecan in elderly patients with advanced colorectal cancer: Preliminary results of a randomized phase II study
    Rosati, G.
    Cordio, S.
    Bordonaro, R.
    Gebbia, V
    Rinalci, A.
    Giannitto, G.
    Borsellino, N.
    Reggiardo, G.
    ANNALS OF ONCOLOGY, 2007, 18 : VII28 - VII29
  • [37] Efficacy, safety and genomic analysis of SCT200, an anti-EGFR monoclonal antibody, in patients with fluorouracil, irinotecan and oxaliplatin refractory RAS and BRAF wild-type metastatic colorectal cancer: a phase II study
    Yang, Lin
    Zhang, Wen
    Fan, Nanfeng
    Cao, Peiguo
    Cheng, Ying
    Zhu, Lingjun
    Luo, Suxia
    Zong, Hong
    Bai, Yuxian
    Zhou, Jianfeng
    Deng, Yanhong
    Ba, Yi
    Liu, Tianshu
    Aili, Mayinuer
    Yin, Xianli
    Gu, Kangsheng
    Dai, Guanghai
    Ying, Jieer
    Shi, Jianhua
    Gao, Yajie
    Li, Wei
    Yu, Guohua
    Xie, Liangzhi
    Gai, Wenlin
    Wang, Yan
    Meng, Peng
    Shi, Yuankai
    EBIOMEDICINE, 2024, 100
  • [38] Phase II trial of biweekly paclitaxel plus infusional 5-fluorouracil and leucovorin in patients with advanced or recurrent inoperable gastric cancer
    Lee, H. J.
    Yun, H. J.
    Kim, S.
    Cho, D. Y.
    Park, J. C.
    Park, S. Y.
    Bae, S. B.
    Lee, K. T.
    Cho, I. S.
    Han, C. S.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 63 (03) : 427 - 432
  • [39] Phase II trial of biweekly paclitaxel plus infusional 5-fluorouracil and leucovorin in patients with advanced or recurrent inoperable gastric cancer
    Hyo Jin Lee
    Do Yeun Cho
    Ji Chan Park
    Sang Byung Bae
    Kyu Taek Lee
    In Sung Cho
    Chang Soon Han
    Suk Young Park
    Hwan Jung Yun
    Samyong Kim
    Cancer Chemotherapy and Pharmacology, 2009, 63
  • [40] A randomized phase II study of biweekly irinotecan monotherapy or a combination of irinotecan plus 5-fluorouracil/leucovorin (mFOLFIRI) in patients with metastatic gastric adenocarcinoma refractory to or progressive after first-line chemotherapy
    Sun Jin Sym
    Junshik Hong
    Jinny Park
    Eun Kyung Cho
    Jae Hoon Lee
    Yeon Ho Park
    Woon Ki Lee
    Min Chung
    Hyung-Sik Kim
    Se Hoon Park
    Dong Bok Shin
    Cancer Chemotherapy and Pharmacology, 2013, 71 : 481 - 488
12345